Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: A model-based evaluation

Vaccine

Volumn 24, Issue 17, 2006, Pages 3500-3504

  De Wals, Philippe ^a,b   Trottier, Pierre ^a   Pépin, Jacques ^c  

^a UNIVERSITÉ LAVAL   (Canada)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Conjugate vaccine; Effectiveness; Immunization program; Meningococcus

Indexed keywords

MENINGOCOCCUS VACCINE;

ARTICLE; BLOOD GROUP TYPING; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; HEALTH PROGRAM; HUMAN; IMMUNIZATION; MENINGOCOCCOSIS; PRIORITY JOURNAL;

ADOLESCENT; CHILD; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION SCHEDULE; INFANT; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MODELS, THEORETICAL; NASOPHARYNX; NEISSERIA MENINGITIDIS, SEROGROUP C; VACCINES, CONJUGATE;

EID: 33645212649     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.02.010     Document Type: Article

References (23)

1. S.G. Squires, and S.L. Deeks Enhanced surveillance of invasive meningococcal disease in Canada; 1 January, 1999, through 31 December, 2001 Can Commun Dis Rep 30 2004 17 28
2. R. Welte, G. van den Dobbelsteen, J.M. Bos, H. de Melker, L. van Halpen, and L. Spanjaard Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in the Netherlands and its impact on decision-making Vaccine 23 2004 470 479
3. H. Theeten, P. Van Damme, F. Carion, and M. van Looveren Vaccinatie tegen meningokokken C in België: kroniek en context van een federaal-regionale campagne Tijdschrift Geneeskunde 59 2003 1239 1251
4. E. Miller, D. Salisbury, and M. Ramsay Planning, registration, and implementation of an immunization campaign against meningococcal serogroup C disease in the UK: a success story Vaccine 20 Suppl. 1 2002 58 67
5. J.F. Murphy Meningococcus C vaccination programme Ir Med J 93 2000 164
6. A. Larrauri, R. Cano, M. Garcia, and S. de Mateo Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain Vaccine 23 2005 4097 4100
7. P. De Wals, V.H. Nguyen, L.J. Erickson, M. Guay, J. Drapeau, and J. St-Laurent Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease Vaccine 22 2004 1233 1240
8. Statistics Canada. Life tables. Canada and Provinces 1990-1992. Catalogue 84-537 Occasional. Ottawa, 1996.
9. Lorange M, Jetté L. Surveillance des infections envahissantes à Neisseria meningitidis. Rapport annuel 2001. Quebec City: Institut national de santé publique, Laboratoire de santé publique du Québec; 2002 (http://www.inspq.qc.ca/pdf/publications/113_Neisseria meningitidis2001.pdf )
10. M.E. Ramsay, N.J. Andrews, C.L. Trotter, E.B. Kaczmarski, and E. Miller Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis Br Med J 326 2003 365 366
11. P. De Wals, G. Deceuninck, N. Boulianne, and G. De Serres Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine JAMA 292 2004 2491 2494
12. P. Richmond, R. Borrow, E. Miller, S. Clark, F. Sadler, and A. Fox Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory J Infect Dis 179 1999 1569 1572
13. P. Richmond, R. Borrow, D. Goldblatt, J. Findlow, S. Martin, and R. Morris Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers J Infect Dis 183 2001 160 163
14. Centers for Disease Control and Prevention. Notice to Readers: Updated recommendations on the use of pneumococcal conjugate vaccine: suspension of recommendation for third and fourth dose. Morbid Mortal Wkly Rep 2004;53:177-8.
15. R. Borrow, D. Goldblatt, N. Andrews, J. Southern, L. Ashton, and S. Deane Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom J Infect Dis 186 2002 1353 1357
16. C.L. Trotter, N.J. Andrews, E.B. Kaczmarski, E. Miller, and M.E. Ramsay Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction Lancet 364 2004 365 367
17. National Advisory Committee on Immunisation. Statement on recommended use of meningococcal vaccines. Can Commun Dis Rep 2001;27(ACS-6):2-36.
18. M.C. Maiden, J.M. Stuart for the UK Meningococcal Carriage Group Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination Lancet 359 2002 1829 1830
19. Trotter CL, Gay NJ, Edmunds WJ. The natural history of meningococcal carriage and disease. Epidemiol Infect 2006, in press.
20. K. Cartwright Meningococcal carriage and disease K. Cartwright Meningococcal disease 1995 John Wiley & Sons Chichester, United Kingdom 115 146
21. C.L.K. Trotter, N.G. Gay, and W.J. Edmunds Dysnamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination Am J Epidemiol 162 2005 89 100
22. B. Hubert, and D.A. Caugant Évolution récente des infections à méningocoque en Europe Eurosurveillance 2 1997 1 3
23. N.E. Rosenstein, B.A. Perkins, D.S. Stephens, L. Lefkowitz, M.L. Cartter, and R. Danila The changing epidemiology of meningococcal disease in the United States, 1992-1996 J Infect Dis 180 1999 1894 1901